700 Participants Needed

Language Interpretation Solutions for Breast Cancer

Recruiting at 7 trial locations
FG
LD
Overseen ByLisa Diamond, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests different methods of providing language interpretation services for breast cancer patients who primarily speak Spanish or Mandarin and have limited English proficiency. It seeks to identify the best method among three options: remote consecutive medical interpreting (RCMI, done after the speaker pauses), remote consecutive video medical interpreting (RCVI), and remote simultaneous medical interpreting (RSMI, done in real-time). The trial seeks patients with Stage II or III breast cancer who are visiting their medical oncologist for the first or second time. As an unphased trial, this study offers a unique opportunity to enhance communication and care for non-English speaking patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that these language interpretation solutions are safe for breast cancer patients with limited English proficiency?

Research has shown that remote medical interpreting methods, such as Remote Consecutive Medical Interpreting (RCMI), Remote Consecutive Video Medical Interpreting (RCVI), and Remote Simultaneous Medical Interpreting (RSMI), are generally well-received by patients. Studies have examined their ability to improve communication without compromising safety. The available research does not report any specific negative effects associated with these methods. They serve as a safe and accurate alternative to traditional in-person interpreting, without introducing new safety concerns. This indicates that participants in these trials are not exposed to additional risks from the interpreting methods being tested.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it's exploring innovative language interpretation methods for breast cancer patients who have limited English proficiency (LEP). Unlike traditional interpreters who are physically present, the trial is testing remote interpreting solutions, including Remote Consecutive Medical Interpreting (RCMI), Remote Consecutive Video Medical Interpreting (RCVI), and Remote Simultaneous Medical Interpreting (RSMI). These methods aim to provide more accessible, flexible, and potentially cost-effective communication between non-English-speaking patients and their healthcare providers. By evaluating these remote solutions, the trial hopes to identify effective ways to improve patient understanding and participation in their treatment plans, ultimately enhancing their overall healthcare experience.

What evidence suggests that this trial's language interpretation solutions could be effective for breast cancer patients with limited English proficiency?

Research has shown that remote medical interpreters can greatly improve patient care, especially for those who have difficulty with English. This trial will compare different remote interpreting methods. Participants may receive Remote Simultaneous Medical Interpreting (RSMI), which studies indicate often leads to fewer medical mistakes and is quicker than other methods. Other participants will receive Remote Consecutive Medical Interpreting (RCMI) or Remote Consecutive Video Medical Interpreting (RCVI), both of which also improve communication between patients and healthcare providers, reducing language barriers. Overall, these methods effectively enhance healthcare experiences for patients who are not fluent in English.12467

Who Is on the Research Team?

Francesca M. Gany, MD, MS - MSK Internist

Francesca Gany, MD, MPH

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for Spanish and Mandarin-speaking breast cancer patients with limited English proficiency, specifically those in stages II and III of the disease. They will be working with English-speaking healthcare providers who do not speak Spanish or Mandarin.

Inclusion Criteria

Phase 1 Providers: Agrees to be audio-record (per self-report)
Phase 2 (clinic staff only; patient participants will be drawn from Phase 1): Is a staff member who works/worked in one of the study clinic sites during the period of Phase 1 RCT study activities
I am a provider who does not speak Spanish and/or Mandarin.
See 7 more

Exclusion Criteria

Phase I Providers: None
I do not have severe psychiatric issues that would stop me from completing study requirements.
Phase 2 (clinic staff only; Phase 1 patient participants follow above criteria): None
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1: Treatment

3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting (RSMI), Remote Consecutive Medical Interpreting (RCMI), and Remote Consecutive Video Medical Interpreting (RCVI) in breast cancer outpatient clinical encounters

4 weeks
Study Visit 1 (post-diagnosis)

Phase 2: Evaluation

Sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data

4 weeks

Follow-up

Participants are monitored for interpretation errors and implementation potential

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Remote Consecutive Medical Interpreting/RCMI
  • Remote Consecutive Video Medical Interpreting/RCVI
  • Remote Simultaneous Medical Interpreting/RSMI
Trial Overview The study compares three types of remote interpreting services during medical appointments: simultaneous interpreting (RSMI), consecutive interpreting (RCMI), and video-based consecutive interpreting (RCVI). It's a randomized trial, meaning participants are randomly assigned to one of these methods.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: Phase II: CFIR mixed-methods explanatory, multi- stakeholder process evaluationExperimental Treatment1 Intervention
Group II: Phase I: Remote Simultaneous Medical Interpreting/RSMI (Arm 1)Experimental Treatment1 Intervention
Group III: Phase I: Remote Consecutive Video Medical Interpreting/RCVI (Arm 3)Experimental Treatment1 Intervention
Group IV: Phase I: Remote Consecutive Medical Interpreting/RCMI (Arm 2)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Published Research Related to This Trial

Breast MRI is primarily used as a complementary tool to mammography and ultrasonography, accounting for 43.6% of cases, and is also important for staging breast cancer in 25.1% of cases.
Despite strong evidence supporting its effectiveness, especially for screening high-risk patients (17.4%), breast MRI remains underutilized in Brazil, indicating a potential gap in patient care.
Indications for breast magnetic resonance imaging at a referral center for the diagnosis and treatment of breast cancer in Brazil.Ferreira, SS., Campos, AM., Fernandes, PL., et al.[2022]
eHealth interventions, like televisits and remote patient monitoring, can significantly improve access to cancer care for patients in both rural and urban communities by overcoming barriers to timely screening and treatment.
Successful implementation of eHealth programs has been shown to enhance patient-provider communication and transform care delivery, ultimately leading to better quality cancer care.
Access to Care: Using eHealth to Limit Location-Based Barriers for Patients With Cancer.Baldwin-Medsker, A., Holland, J., Rodriguez, ES.[2021]
The remote-simultaneous interpretation service led to significantly more communication during postpartum visits, with 10% more physician utterances and 28% more mother utterances compared to traditional interpretation methods.
Both mothers and physicians preferred the remote-simultaneous interpretation service, which also resulted in fewer inaccuracies in communication, suggesting it enhances understanding in medical encounters for non-English-speaking patients.
Eliminating language barriers for non-English-speaking patients.Hornberger, JC., Gibson, CD., Wood, W., et al.[2021]

Citations

rsmi heals - NIH RePORTERWe will compare three types of technology-enabled human-delivered interpreting solutions in a study with limited English proficient breast cancer patients.
A Study of Language Interpretation Solutions for People ...The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical ...
Language Interpretation Solutions for Breast CancerResearch shows that telehealth, which includes remote interpreting, improves patient access to care, early diagnosis, and treatment, especially in remote areas.
Effectiveness of interpreters and other strategies for ...This is the first systematic review comparing strategies for mitigating language barriers. In healthcare, professional interpreters and shared language were ...
A Study of Language Interpretation Solutions for People ...A Study of Language Interpretation Solutions for People With Breast Cancer ... Remote Consecutive Medical Interpreting/RCMI. Remote Simultaneous ...
Remote Symptom Alerts and Patient-Reported Outcomes ...Symptom surveillance using a remote symptom monitoring (RSM) platform enables the capture and reporting of patient-reported outcomes (PROs) from home.
Project DetailsWe will compare RCMI (audio consecutive) (Arm 1), versus RSMI (UN style) (Arm 2) and versus AISMI (AI UN style) (Arm 3) with actors who speak various languages ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security